GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Orthofix Medical Inc (NAS:OFIX) » Definitions » Return-on-Tangible-Equity

Orthofix Medical (Orthofix Medical) Return-on-Tangible-Equity : -30.27% (As of Dec. 2023)


View and export this data going back to 1992. Start your Free Trial

What is Orthofix Medical Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Orthofix Medical's annualized net income for the quarter that ended in Dec. 2023 was $-88.7 Mil. Orthofix Medical's average shareholder tangible equity for the quarter that ended in Dec. 2023 was $293.0 Mil. Therefore, Orthofix Medical's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 was -30.27%.

The historical rank and industry rank for Orthofix Medical's Return-on-Tangible-Equity or its related term are showing as below:

OFIX' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -60.02   Med: -2.41   Max: 6.23
Current: -51.64

During the past 13 years, Orthofix Medical's highest Return-on-Tangible-Equity was 6.23%. The lowest was -60.02%. And the median was -2.41%.

OFIX's Return-on-Tangible-Equity is ranked worse than
74.45% of 767 companies
in the Medical Devices & Instruments industry
Industry Median: 1.97 vs OFIX: -51.64

Orthofix Medical Return-on-Tangible-Equity Historical Data

The historical data trend for Orthofix Medical's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orthofix Medical Return-on-Tangible-Equity Chart

Orthofix Medical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -13.77 1.21 -18.05 -9.16 -60.02

Orthofix Medical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.05 -87.45 -47.68 -37.12 -30.27

Competitive Comparison of Orthofix Medical's Return-on-Tangible-Equity

For the Medical Devices subindustry, Orthofix Medical's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orthofix Medical's Return-on-Tangible-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Orthofix Medical's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Orthofix Medical's Return-on-Tangible-Equity falls into.



Orthofix Medical Return-on-Tangible-Equity Calculation

Orthofix Medical's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-151.395/( (218.155+286.306 )/ 2 )
=-151.395/252.2305
=-60.02 %

Orthofix Medical's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=-88.696/( (299.695+286.306)/ 2 )
=-88.696/293.0005
=-30.27 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Orthofix Medical  (NAS:OFIX) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Orthofix Medical Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Orthofix Medical's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Orthofix Medical (Orthofix Medical) Business Description

Traded in Other Exchanges
Address
3451 Plano Parkway, Lewisville, TX, USA, 75056
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two main segments: global spine, including bone growth and healing therapies, spinal implants, and regenerative tissue products; and global orthopedics, providing products used in fracture repair, deformity correction, and bone reconstruction procedures. The majority of the company's sales come from the global spine segment in the United States. Orthofix distributes its products throughout North America, Europe, and several countries globally. The company provides solutions to hospitals, physicians, other healthcare providers, and patients.
Executives
James F. Hinrichs director 3750 TORREY VIEW COURT, SAN DIEGO CA 92130
Puja Leekha officer: CECO & Interim CLO 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Geoffrey C Gillespie officer: VP, Controller, Interim CFO 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Kevin J. Kenny officer: President of Global Spine C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Shweta Maniar director C/O SEASPINE HOLDINGS CORP, 5770 ARMADA DRIVE, CARLSBAD CA 92008
Stuart Essig director 311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
John J. Bostjancic officer: CFO C/O SEASPINE HOLDINGS CORPORATION, 2302 LA MIRADA DRIVE, VISTA CA 92081
Keith Valentine director, officer: President & CEO 7475 LUSK BLVD., SAN DIEGO CA 92121
Henneman John B Iii director 311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Patrick L Keran officer: Chief Legal Officer 6725 MESA RIDGE RD., SUITE 100, SAN DIEGO CA 92121
Thomas A. West director C/O INTERSECT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Michael E Paolucci director 7475 LUSK BLVD., SAN DIEGO CA 92121
Catherine M Burzik director
Rice Doug officer: CFO 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Kimberley A. Elting officer: Chief Legal Officer 3451 PLANO PARKWAY, LEWISVILLE TX 75056

Orthofix Medical (Orthofix Medical) Headlines

From GuruFocus